Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Xbiotech Inc
(NQ:
XBIT
)
6.580
+0.460 (+7.52%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Xbiotech Inc
< Previous
1
2
Next >
XBIT Stock Earnings: XBiotech Reported Results for Q2 2024
August 12, 2024
XBiotech just reported results for the second quarter of 2024.
Via
InvestorPlace
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?
June 18, 2024
XBiotech reveals results from its Phase 1/Phase 2 1-BETTER Study for advanced pancreatic cancer, highlighting the safety and tolerability of Natrunix with the ONIVYDE + 5-Fluorouracil + Leucovorin...
Via
Benzinga
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
June 18, 2024
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy
From
XBiotech Inc.
Via
GlobeNewswire
XBIT Stock Earnings: XBiotech Reported Results for Q1 2024
May 13, 2024
XBiotech just reported results for the first quarter of 2024.
Via
InvestorPlace
XBIT Stock Earnings: XBiotech Reported Results for Q4 2023
March 18, 2024
XBiotech just reported results for the fourth quarter of 2023.
Via
InvestorPlace
Stocks That Hit 52-Week Lows On Thursday
October 20, 2022
Thursday saw 177 companies set new 52-week lows.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 22, 2024
Via
Benzinga
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
January 04, 2024
From
XBiotech Inc.
Via
GlobeNewswire
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
November 14, 2023
(Phase II Multicenter Study is Proceeding Well with High Anticipation)
From
XBiotech Inc.
Via
GlobeNewswire
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
September 26, 2023
From
XBiotech Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 05, 2023
Via
Benzinga
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
August 30, 2023
From
XBiotech Inc.
Via
GlobeNewswire
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
August 08, 2023
From
XBiotech Inc.
Via
GlobeNewswire
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
May 22, 2023
XBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment
From
XBiotech Inc.
Via
GlobeNewswire
Why Doximity Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
May 17, 2023
Gainers
Via
Benzinga
Dow Jumps Over 100 Points; US Housing Starts Rise In April
May 17, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.37% to 33,135.37 while the NASDAQ rose...
Via
Benzinga
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
May 17, 2023
From
XBiotech Inc.
Via
GlobeNewswire
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
April 17, 2023
Hutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke
From
XBiotech Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
November 28, 2022
On Monday, 79 companies reached new 52-week lows.
Via
Benzinga
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer
October 13, 2022
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in France
From
XBiotech Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
August 22, 2022
On Monday, 195 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
July 14, 2022
On Thursday, 550 companies achieved new lows for the year.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
September 22, 2022
On Thursday, 1076 companies hit new 52-week lows.
Via
Benzinga
The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial
June 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 20, 2022
On Tuesday, 507 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
September 19, 2022
On Monday, 429 stocks made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
August 31, 2022
On Wednesday, 238 companies achieved new lows for the year.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
August 01, 2022
On Monday, 92 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
June 02, 2022
During the Thursday's session, 100 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
May 24, 2022
On Tuesday, 540 companies set new 52-week lows.
Via
Benzinga
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.